Abstract: The present disclosure relates to a battery, and more particularly to a battery electrode. According to some implementations of the present disclosure, a method for manufacturing a battery electrode includes: forming a mixture of a polymer powder and an active material into a fiber; weaving the fiber into a woven film; and carbonizing the woven film.

Abstract: An aerosol generating device includes a housing including an accommodation space in which an aerosol generating article is accommodated and an air flow path through which fluid moves inside the housing, wherein a volume of the air flow path is variable.

Abstract: An aerosol generating device includes: a housing including a hole for receiving an aerosol generating article and a guide apart from the hole; and a cover configured to move along the guide between a first position and a second position to open or close the hole, wherein the hole is open when the cover is located in the first position, and the hole is closed when the cover is located in the second position.

Abstract: In an embodiment a method includes manufacturing a membrane-electrode-gas diffusion layer assembly (MEGA) fabric by bonding a gas diffusion layer (GDL) material to a first surface of a membrane-electrode assembly (MEA) fabric, injecting, by a steam injector, a liquid material to a first surface of the MEGA fabric while allowing the liquid material to be absorbed to the first surface of the MEGA fabric, supplying, by a gas injector, compressed gas to a second surface of the MEGA fabric in which the liquid material has been absorbed, inspecting, by a surface inspection device, a surface state of the MEGA fabric after supplying the compressed gas and, after inspecting, winding the MEGA fabric around a MEGA winding unit.

Abstract: One aspect provides a pharmaceutical composition and a pharmaceutical combination formulation contains the same, the pharmaceutical composition containing as active ingredients: a proton pump inhibitor or a pharmaceutically acceptable salt thereof; and an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: The present invention relates to a toothbrush type recommendation apparatus. The toothbrush type recommendation apparatus comprises: a user input unit; an output unit; and an operation control unit connected to the user input unit and the output unit.

Abstract: A device is provided for performing a pressure test on a battery module. The device may include a module case in which battery cells are accommodated, a pressure plate installed in a middle portion of the module case in a width direction and configured to pressurize the battery cells toward the module case, a pressure driver configured to apply a pressure to the pressure plate, and a controller configured to control a pressure force and a pressure pattern with respect to the battery cells. The pressure plate may be configured to simulate expansion and contraction of the battery cells by repeatedly pressurizing and depressurizing the battery cells.

Abstract: A method of controlling a wireless power receiver can include transmitting, during a first determination phase, a foreign object detection status packet; before entering a first power transfer mode for receiving first power and before entering a second power transfer mode for receiving second power, receiving a determination result as to whether a foreign object is present determined based on the foreign object detection status packet; in response to determining that the foreign object is present based on the determination result, receiving the first power according to the first power transfer mode; and in response to determining that the foreign object is not present based on the determination result, receiving the second power according to the second power transfer mode.

Abstract: Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.

Abstract: Provided are a pharmaceutical composite formulation and a method of preparing the same, the pharmaceutical composite formulation including: a first layer containing, as an active ingredient, a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant, and a second layer containing, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, and a mixture thereof.

Abstract: According to an aspect, provided are a composite tablet and a method of preparing the composite tablet, wherein the composite tablet may include a first layer including dry granules that include sitagliptin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and dapagliflozin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a second layer including wet granules that include metformin or a pharmaceutically acceptable salt thereof and colloidal silicon dioxide.

Abstract: The present disclosure discloses a method for preparing a hybrid-type fluorine-based nonionic surfactant capable of producing a high purity material in a high yield. By preparing a hybrid-type fluorine-based nonionic surfactant according to the present disclosure, the surfactant is mass-produced in a high yield through controlling reaction conditions including a solvent.

Abstract: An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: The present invention relates to a pharmaceutical preparation comprising a granule comprising a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a diluent. The pharmaceutical preparation has a high productivity of the preparation due to excellent tableting properties, friability, and mass uniformity. The pharmaceutical preparation has low generated amount of impurities and high stability.

Abstract: Disclosed are an acid-resistant pharmaceutical composition including tamsulosin hydrochloride, and a method of preparing the same. The pharmaceutical composition is formulated into tablets by preparing core beads including tamsulosin hydrochloride as an active ingredient, coating the core beads with an entering coating solution including a specific amount of plasticizer, adding a post mixture portion including a buffer to adjust density and a lubricant to the enteric-coated core beads, and performing tableting. The enteric coating layer is not broken during the tableting process. Thus, the acid resistance of the pharmaceutical composition is maintained. The pharmaceutical composition can be easily formulated into tablets, ensures good uniformity of dosage unit, lowers dissolution rate of tamsulosin hydrochloride, has good acid resistance, and is stable not to exhibit signification decomposition of tamsulosin hydrochloride.

Abstract: A semiconductor light emitting device includes a plurality of light emitting structures, an isolation layer covering side surfaces of the plurality of light emitting structures and insulating the plurality of light emitting structures from one another, a partition layer formed on the isolation layer, a first protective layer covering top surfaces of the plurality of light emitting structures and side walls of the partition layer, a reflective layer covering the first protective layer and disposed on the side walls of the partition layer, and a second protective layer covering the reflective layer.

Abstract: Provided is an oral pharmaceutical formulation including sustained-release pellets containing tamsulosin hydrochloride and a pharmaceutically acceptable additive, wherein the sustained-release pellets includes about 50 wt % to about 100 wt % of particles having a particle size of about 0.50 mm to about 0.85 mm, and less than about 15 wt % of particles having a particle size less than about 0.50 mm. The oral pharmaceutical formulation may have a reduced deviation in dissolution rate of tamsulosin hydrochloride and improved content uniformity among unit dosage forms, and have ensured quality due to high reproducibility of unit dosage forms.

Abstract: The present invention relates to a method for detecting a foreign material, and a device and system therefor.

Abstract: A battery module includes a plurality of secondary batteries, each including an electrode assembly and an electrolyte accommodated in an inner space of an exterior case. The battery module also includes an electrode lead having a body and a plate-shaped head portion. A first end of the body is electrically connected to a positive electrode plate or the a negative electrode plate of the electrode assembly, and a second end of the body protrudes outward from the exterior case. The plate-shaped head extends in both directions perpendicular to the protruding direction of the body from the second end. The battery module also includes a bus bar having a plate shape with a slit extending inwardly from one end thereof so as to receive a portion of the body. The electrode lead and the bus bar may be at least partially made of an electrically conductive material.

Abstract: The present invention relates to a light emission control device for inhibiting accumulation of amyloid beta plaques, wherein light emission is controlled whereby nerve endings distributed in the epidermis or dermis layer under the skin surface within a specific region of the neck and the nape of the neck in an animal or human body are simulated with visible light energy for a predetermined period of time, and nitrergic nerve terminals connected to the stimulated nerve endings and the nervous system are induced to secrete a material, such as nitric oxide, which in turn relaxes the cerebral blood veins or lymphatic vessels in contact with the nitrergic nerve terminals to induce cerebral blood circulation or lymph circulation enhancement, thereby inhibiting the accumulation of amyloid beta plaques.